Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1999-04-22
2002-08-06
Saidha, Tekchand (Department: 1652)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S195000, C435S252300, C435S018000, C514S449000, C514S895000
Reexamination Certificate
active
06428983
ABSTRACT:
BACKGROUND OF THE INVENTION
Parasitic protozoa are responsible for a wide variety of infections in man and animals. Many of the diseases are life threatening to the host and cause considerable economic loss in animal husbandry. For example, malaria remains a significant health threat to humans despite massive international attempts to eradicate the disease; trypanosomiasis such as Chagas disease caused by
Trypanosoma cruzi
and African sleeping sickness caused by
T. brucei
are not uncommon in Africa and South America; and opportunistic infections in immunocompromised hosts caused by
Pneumocystis carinii, Toxoplasma gondii,
Cryptosporidium sp. are becoming increasingly significant in the developed countries.
A protozoal infection of great economic importance is coccidiosis, a widespread disease of domesticated animals produced by infections by protozoa of the genus Eimeria. Some of the most significant of Eimeria species are those in poultry namely
E. tenella, E. acervulina, E. necatrix, E. brunetti
and
E. maxima.
The disease is responsible for high levels of morbidity and mortality in poultry and can result in extreme economic losses.
In some protozoal diseases, such as Chagas disease, there is no satisfactory treatment; in others, drug-resistant strains of the protozoa may develop. Accordingly, there exists a continued need to identify new and effective anti-protozoal drugs. However, antiparasitic drug discovery has been, for the most part, a random and laborious process through biological screening of natural products and synthetic compounds against a panel of parasites. This process can be greatly facilitated and made more specific if a target of antiprotozoal drugs can be identified, and incorporated into the screening process.
Histone deacetylase and histone acetyltransferase together control the net level of acetylation of histones. Inhibition of the action of histone deacetylase results in the accumulation of hyperacetylated histones, which in turn is implicated in a variety of cellular responses, including altered gene expression, cell differentiation and cell-cycle arrest. Recently, trichostatin A and trapoxin A have been reported as reversible and irreversible inhibitors, respectively, of mammalian histone deacetylase (see e.g., Yoshida et al, Bioassays, 1995, 17(5):423-430). Trichostatin A has also been reported to inhibit partially purified yeast histone deacetylase (Sanchez del Pino et al, Biochem. J., 1994, 303:723-729). Trichostatin A is an antifungal antibiotic and has been shown to have anti-trichomonal activity as well as cell differentiating activity in murine erythroleukemia cells, and the ability to induce phenotypic reversion in sis-transformed fibroblast cells (see e.g. U.S. Pat. No. 4,218,478; Yoshida et al, Bioassays, 1995, 17(5):423-430 and references cited therein). Trapoxin A, a cyclic tetrapeptide, induces morphological reversion of v-sis-transformed NIH3T3 cells (Yoshida and Sugita, Jap. J. Cancer Res., 1992, 83(4):324-328). The present inventors have found that a number of cyclic tetrapeptides structurally related to trapoxin A are inhibitors of histone deacetylase, and also possess antiprotozoal activity.
SUMMARY OF THE INVENTION
The present invention relates to histone deacetylase as a target for antiprotozoal agents. More particularly, the invention concerns a method for identifying potential antiprotozoal agents by determining whether a test compound is capable of inhibiting the action of histone deacetylase. The invention also concerns a method for treating protozoal infections by administering to a host suffering from protozoal infection a therapeutically effective amount of a compound that inhibits histone deacetylase.
REFERENCES:
patent: 4218478 (1980-08-01), Omura et al.
patent: 5356927 (1994-10-01), Taraschi et al.
patent: 406725 (1991-09-01), None
patent: 07196686 (1995-01-01), None
Kervabon et al. (1979) FEBS Letters 106: 93-96.*
Lechner, et al., Biochem, et Biophysica Acta, vol. 1926, No. 2, pp. 181-188 (1996).
Brosch, et al., The Plant Cell, vol. 7, No. 11, pp. 1941-1950 (1995).
Kervabon, et al., Febs Letters, vol. 106, No. 1, pp. 93-96 (1979).
Bioassays, 17(5): p. 423 (1995).
J. Biol. Chem. 268(30): p. 22429 (1993).
J. Antibiot., 43(12): p. 1524 (1990).
Acta Cryst. C., 47: p. 1469 (1991).
Jap. J. Cancer Res., 83(4): p. 324 (1992).
J. Med. Chem., 30: p. 71(1987).
Experientia, 41: p. 348 (1985).
Biochimie, 71: p. 71 (1989).
Tet. Lett., 35(33): p. 6009 (1994).
Biochem., 22: p. 3507 (1983).
J. Med. Chem., 24: p. 567 (1981).
Amino Acids, 6(3): p. 315 (1994).
Biochem., 22: p. 3502 (1983).
Eur. J. Cancer, 10:801 (1974).
Phytopathology, 57: p. 1169 (1967).
Biochem. Biophys. Res. Comm. 107:785 (1982).
Bioch J., 1994, 303: pp. 723-729.
J. Biol. Chem., 1990, 265:17174.
Patent Abstracts of Japan, vol. 95, No. 8, Koji, et al. JP 07196686A.
M. Yoshida, et al., J. Antibiot. (Tokyo), 43(9):1101-1106 (1990).
M. Yoshida, et al., J. Biological Chem., 265(28):17174-17179 (1990).
Dulski Paula M.
Gumett Anne M.
Myers Robert W.
Rattray Sandra J.
Schmatz Dennis M.
Lee Shu M.
Merck & Co.
Rose David L.
Saidha Tekchand
Yang Mollie M.
LandOfFree
Histone deacetylase as target for antiprotozoal agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histone deacetylase as target for antiprotozoal agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histone deacetylase as target for antiprotozoal agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2927951